Equity Profile

LEGN

Legend Biotech Corporation

Health CareBiotechnology$3.9B

Dec1Thu

Pre-Earnings Brief

UpcomingQ1-2026After Close5:00 PM EST

Company Snapshot

Legend Biotech Corporation operates in the biotechnology sector, focusing on developing innovative therapies for cancer treatment. With a market cap of $4 billion, the company is part of a rapidly evolving industry that is increasingly important for healthcare advancements.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market demand and operational success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

In the last quarter, Legend Biotech reported an EPS of -$0.16, which was better than the expected -$0.29, resulting in a positive surprise. However, revenue details were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Legend Biotech's upcoming earnings report, especially given its history of beating EPS estimates. However, the lack of revenue guidance adds a layer of uncertainty.

Bull Case

If the company continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing guidance, it could lead to a negative reaction in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue figures can management provide for the current quarter?

Revenue figures will be critical for assessing the company's market performance and growth trajectory, especially given the lack of guidance.

How does Legend Biotech plan to address any operational challenges faced in the last quarter?

Management's response to operational challenges will be important for investor confidence and future growth prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Legend Biotech to exceed revenue expectations based on its recent operational improvements.

Supporting Evidence

The company has a history of beating EPS estimates, which could indicate stronger underlying performance than anticipated.

Options pricing suggests a lower expected move compared to historical averages, indicating that the market may not be fully pricing in potential positive surprises.

Key Risk

If revenue growth comes in above 15%, it could significantly shift investor sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will indicate whether the company can maintain its growth trajectory amidst industry challenges.

Bull Confirmed If

A revenue growth rate of at least 15% year-over-year would confirm the bullish case.

Bear Confirmed If

If the company reports an EPS loss greater than -$0.25, it would confirm the bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±5%

Historical Avg

±6.1%

Pricing cheap

The options market is pricing in a 5% potential move in either direction following the earnings report, indicating uncertainty among investors.

Options are pricing ±5.0% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing cheap.

Detail

30d HV

72.4%

Calls (40K)P/C Ratio: 0.32Puts (11K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations, history suggests a potential stock increase of around 1.71%, confirming positive investor sentiment.

In-Line / Cautious

A cautious in-line report could lead to muted reactions, as investors await clearer guidance on future performance.

Miss

If the company misses expectations, history suggests a possible decline of around 6.91%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new therapies in the pipeline and their expected timelines.
2Management's commentary on market demand for their products.
3Details on operational efficiencies and cost management strategies.
4Insights into competitive positioning within the biotechnology sector.
5Future guidance on revenue expectations and growth strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Elbit Systems Ltd.

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market demand and operational success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

LEGN Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 6Q

EPS Beat Streak

EPS Beat Rate

67%

Avg EPS Surprise

+12.73%

Avg Stock Reaction

+3.44%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If the company continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing guidance, it could lead to a negative reaction in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue figures can management provide for the current quarter?

Revenue figures will be critical for assessing the company's market performance and growth trajectory, especially given the lack of guidance.

How does Legend Biotech plan to address any operational challenges faced in the last quarter?

Management's response to operational challenges will be important for investor confidence and future growth prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Legend Biotech to exceed revenue expectations based on its recent operational improvements.

Supporting Evidence

The company has a history of beating EPS estimates, which could indicate stronger underlying performance than anticipated.

Options pricing suggests a lower expected move compared to historical averages, indicating that the market may not be fully pricing in potential positive surprises.

Key Risk

If revenue growth comes in above 15%, it could significantly shift investor sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal as it will indicate whether the company can maintain its growth trajectory amidst industry challenges.

Bull Confirmed If

A revenue growth rate of at least 15% year-over-year would confirm the bullish case.

Bear Confirmed If

If the company reports an EPS loss greater than -$0.25, it would confirm the bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±5%

Historical Avg

±6.1%

Pricing cheap

The options market is pricing in a 5% potential move in either direction following the earnings report, indicating uncertainty among investors.

Options are pricing ±5.0% while LEGN has averaged ±6.1% over the last 6 prints — setup is pricing cheap.

Detail

30d HV

72.4%

Calls (40K)P/C Ratio: 0.32Puts (11K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Legend Biotech beats expectations, history suggests a potential stock increase of around 1.71%, confirming positive investor sentiment.

In-Line / Cautious

A cautious in-line report could lead to muted reactions, as investors await clearer guidance on future performance.

Miss

If the company misses expectations, history suggests a possible decline of around 6.91%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new therapies in the pipeline and their expected timelines.
2Management's commentary on market demand for their products.
3Details on operational efficiencies and cost management strategies.
4Insights into competitive positioning within the biotechnology sector.
5Future guidance on revenue expectations and growth strategies.